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Deep sequencingThe recently approved ALK kinase inhibitor crizotinib has demonstrated successful treatment of metastatic and
late stage ALK fusion positive non-small cell lung cancer (NSCLC). However, the median duration of clinical
beneﬁt is ~10–11 months due to the emergence of multiple and simultaneous resistance mechanisms in
these tumors. Mutations in the ALK kinase domain confer resistance to crizotinib in about one-third of
these patients.We developed amultiplex deep sequencingmethod using semiconductor sequencing technology
to quickly detect resistance mutations within the ALK kinase domain from tumor biopsies. By applying a
base-pair speciﬁc error-weightedmutation calling algorithm (BASCA) that we developed for this assay, genomic
DNA analysis from thirteen relapsed patients revealed three known crizotinib resistance mutations, C1156Y,
L1196M and G1269A. Our assay demonstrates robust and sensitive detection of ALK kinase mutations in
NSCLC tumor samples and aids in the elucidation of resistance mechanisms pertinent to the clinical setting.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Crizotinib was approved by US FDA in 2011 as a ﬁrst-in-class, oral,
small-molecule anaplastic lymphoma kinase (ALK) inhibitor for the
treatment of ALK fusion positive advanced non-small cell lung cancer
(NSCLC). Phase I and II clinical trials of crizotinib showed an objective re-
sponse rate of 50–61% with median response durations of 42–48 weeks,
and amedian progression-free survival (PFS) of 10–11 months [1,2]. The
frequency of ALK rearrangements in the overall population of NSCLC
patients is 3–5% or ~45,000 patients worldwide each year [3]. The
rearranged ALK gene and its fusion partner mediate ligand-
independent oligomerization of ALK and constitutive kinase activation.
Tumors possessing ALK rearrangement such as EML4-ALK become
oncogenically addicted to ALK signaling, and at the same time make
them vulnerable to ALK inhibitors [4–6]. However, many patients with
initial encouraging responses later developed resistance. About
one-third of the patients with acquired resistance to crizotinib haveience Center Drive, San Diego,
ine, Samsung Medical Center,
10, Seoul, Korea.
(D. Huang), kpark@skku.edu
study.
rights reserved.secondarymutations in the ALK tyrosine kinase domain or ampliﬁcation
of the ALK fusion gene [7–9]. ALK resistance mutations vary widely
within the tyrosine kinase domain. So far, nine different acquired resis-
tance mutations have been identiﬁed from crizotinib treated NSCLC
patients, including 1151Tins, L1152R, C1156Y, F1174C, L1196M,
G1202R, D1203N, S1206Y and G1296A [7–10,17]. Another third of
the crizotinib-resistant patients' tumors possess bypass mechanisms
via activation of EGFR, KIT or KRAS, and the last third of refractory
patients have undetermined resistance mechanisms [8,9]. Efforts
are underway to develop second generation ALK inhibitors that are
more potent towards ALK kinase domain mutations. Therefore, assays
that can detect ALK kinasemutations from tumor biopsiesmay improve
clinical outcomes. Several highly sensitive platforms exist to detect low
frequency mutations in very heterogeneous biopsy samples. Of these
technologies including primer extension [8,11], allele speciﬁc PCR
[12], pyrosequencing [13], BEAMing [14] and droplet digital PCR [15],
next generation deep sequencing technology stands out as the optimal
interrogation platform because it can detect novel mutations and
requires a small amount of specimens. We utilized the Ion Torrent
Personal Genome Machine (PGM) to deep sequence the entire ALK
kinase domain of tumor DNA from NSCLC patients who have relapsed
after crizotinib treatment. Our assay identiﬁed three previously
reported resistance mutations in three of thirteen patients' tumor biopsy
samples.
Table 1
Detection limit of mutation G1269A with the presence of wild type ALK.
% G1269A allele Total reads Number of reads with G1269A allele
20.0% 2731 546 (20.0%)
10.0% 2291 180 (7.9%)
5.0% 2138 100 (4.7%)
2.5% 2769 82 (2.9%)
1.25% 2500 46 (1.8%)
0% 2322 0 (0%)
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The assay was used to detect ALK kinase domain mutations from
crizotinib-resistant NCI-H3122 clones derived in vitro. Using this
technology, a G1269A mutation was identiﬁed in clone 1-07 with
20% allele frequency and a total of 2731 reads of bidirectional coverage.
This mutation was also conﬁrmed by Sanger sequencing (data not
shown). With an abundance of gDNA from a resistant cell line, we
proceeded to determine the sensitivity of this assay running on an Ion
Torrent deep sequencing platform using spike-in titration experiments.
Genomic DNA from the crizotinib-resistant clone 1-07 was spiked into
different amounts of a human male normal genomic DNA. The amount
of G1269A mutation ranged from 1.25%–20% of the total ALK genes
presence. The full sensitivity range is summarized in Table 1 where
the G1269A mutation was detectable at the level as low as 1.25%.
However, average sequencing noise level ~0.13% was determined
and observed by examining ~67 base-pairs ﬂanking region of the
codon G1269 in exon 25 from the human male normal sample se-
quencing reads with a standard deviation of 0.21%. Therefore, we
should be able to call mutation G1269A above 0.8% (average noise
plus 3× standard deviation) threshold with 99% conﬁdence. Overall,
the highest noise level in all exons 21–27 observed in the human
male normal sample was about 3%.
Each patient DNA sample was ampliﬁed with barcoded fusion
primer pairs and bi-directionally sequenced on two Ion Torrent 314
chip in two independent sequencing runs (Fig. 1). Since the sequencing
adapters and barcodes were built into the target speciﬁc primers, se-
quencing libraries were formed during the PCR step (Fig. 1). PCR
amplicons were pooled into a single tube for deep sequencing on
an Ion Torrent PGM. Results showed an excess of 500× coverage
from either direction covering exons 21–27 of ALK kinase domain
in all samples. Mean quality score Q20 read length was approximately
148 bps, andmutationswere identiﬁedwith bases different from refer-
ences but of whose quality scoreswere higher and equal to 20. Thirteen
tumor samples were collected from the patients who were relapsed
post crizotinib treatment. Two of the patients included archived pre-
treatment FFPE specimens (Patients 5 and 6). Source materials from
these patients included a lung primary tumor resection, metastatic
liver tumor biopsy, metastatic bone tumor excision, metastatic adrenal5’-CCTCTCTATGGGCAGTCGGTGAT
trP1
Amplicon of ALK Kinase Dom
-3’
A
Amplic
3’
Barcode 
5’-CCATCTCATCCCTGCGTGTCTCCGACTCAG
TSF
TSF
Fig. 1. Barcoded fusion primers. One fusion primer pair has the A adapter (A) region followed
the proximal end of the targeted ALK exon sequence, and the other has the truncated P1 ada
end of the target ALK exon sequence. The other fusion primer pair has the adapter sequences
bidirectional sequencing of each exon region. This is the same for exons 21–27 of ALK kinatumor excision, bronchoscopic biopsy and pleural ﬂuid (Table 2). Each
sample was sectioned, H&E stained, and examined for tumor cell con-
tent. Pathology reports showed tumor content ranging from 10–90%.
All ALK kinase domain exons from all thirteen patients including
archived FFPE materials were ampliﬁed successfully. Each sample was
ampliﬁed with barcoded fusion primer pairs and bi-directionally se-
quenced on an Ion Torrent PGM (Fig. 1).
Instead of using an arbitrary cutoff across the seven exons of ALK ki-
nase domain sequenced by PGM (~1 kb), we developed a base-pair spe-
ciﬁc error-weighted mutation calling algorithm (BASCA) for detecting
mutations by assessing the noise level at each single base-pair in order
to increase the accuracy of mutation calling. Three unique mutations
were identiﬁed from three tumors by BASCA after ﬁltered out known
SNPs and manual inspection to eliminate two false positive calls in the
sequencing error-prone regions. Patient 2's bone metastatic tumor
sample revealed a known mutation G1269A with 15% allele frequency
(Fig. 2A). This call was supported by a total of 10,590 readswith bidirec-
tional coverage. Interestingly, Patient 2 partially responded to crizotinib
treatment but relapsed after 12 months with metastatic tumors found
in the bone. For Patient 7, normal and tumor regions were dissected
from a single parafﬁn block of a liver biopsy. No mutations were
detected in the normal liver tissue. However, a mutation, C1156Y, was
detected in the metastatic tumor sample with 14% allele frequency.
This ﬁnding was supported with 1973 reads including bidirectional
coverage (Fig. 2B). Patient 7 was an initial crizotinib responder
who relapsed after 8 months with liver metastasis. In Patient 8's
lung core biopsy tumor sample, the “gatekeeper” mutation L1196M
was identiﬁed with 12% allele frequency (Fig. 2C). This call was
supported by a total of 12,269 readswith bidirectional coverage. Patient
8 achieved partial response to crizotinib for 7 months as the 7th line of
therapy but progressed in the liver and brain.
Nomutationswere detected in the ALK kinase domain in the rest ten
patients. In addition, no preexisting mutations were found in the
archived materials from Patients 5 and 6 prior to crizotinib treatment
(Table 2). Tumor samples from Patients 1, 2, 5 and 6 were also
examined by Sanger sequencing and allele speciﬁc PCR [18]. These
results were concordant with the Ion Torrent PGM deep sequencing
data, i.e. G1269A mutation was detected in Patient 2's pleural effusion
sample (a different material from the patient) and no mutation was
detected in the samples from Patients 1, 5 and 6 [18].
3. Discussion
After the recent approval of crizotinib by US FDA, most ALK fusion
positive NSCLC patients will have signiﬁcant clinical beneﬁt from the
drug. However, it is plausible that acquired resistance may ensue like
other targeted tyrosine kinase inhibitor (TKI) therapeutics [16]. In
this study, we successfully developed a molecular assay capable of
detecting three known resistant mutations in the ALK kinase domainGACTCAGCCTCTGTGCGTCCCTACTCTACC-5’
A
ain
Barcode 
3’-
on of ALK Kinase Domain
3’-
trP1
TAGTGGCTGACGGGTATCTCTCC-5’
TSR
TSR
by a barcode sequence, then followed by the template-speciﬁc forward primer (TSF) in
pter (trP1) region followed by the template-speciﬁc reversed primer (TSR) in the distal
A and trP1 swapped. Two primer pairs per exon region generate two libraries to enable
se domain.
Table 2
Summary of sequencing results of all materials from thirteen patients.
Patient ID Sampling Sample type Tumor content (%) Mutation Conﬁrmed by
1 Post treatment Liver metastasis 50 Not detected Sanger⁎
2 Post treatment Bone metastasis 90 G1269A (15%) Sanger and AS-PCR⁎
3 Post treatment Pleural ﬂuid 70 Not detected
4 Post treatment Adrenal metastasis 50 Not detected
5 Pretreatment
Post treatment
Lung primary
Bronchoscopic biopsy
40
30
Not detected
Not detected
Sanger⁎
6 Pretreatment
Post treatment
Bone metastasis
Liver metastasis
70
80
Not detected
Not detected
Sanger⁎
7 Post treatment
Post treatment
Normal liver tissue
Liver metastasis
0
70
Not detected
C1156Y (14%)
8 Post treatment Liver metastasis 70 L1196M (12%)
9 Post treatment Lung core biopsy N/A Not detected
10 Post treatment Chest wall soft tissue N/A Not detected
11 Post treatment Lung core biopsy 50 Not detected
12 Post treatment Neck lymph node 80 Not detected
13 Post treatment Adrenal metastasis 10 Not detected
⁎conﬁrmation performed by Sanger sequencing and allele speciﬁc PCR (AS-PCR) [18].
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ment with the other studies that about one-third of the crizotinib ac-
quired resistant tumors harbor secondary mutations. These three
mutations, C1156Y, L1196M and G1269A, were previously reported to
be present in crizotinib-refractory patients [7,8]. C1156Y was ﬁrst
reported alongside the gatekeeper mutation L1196M, in a Japanese pa-
tientwho relapsed after 5 months of crizotinib therapy. C1156Y is posi-
tioned adjacent to the N-terminal helixαC and induces conformational
changes that negatively affect the binding activity of crizotinib to ALK
[7]. G1269Awas previously found in two patientswho confer resistance
to crizotinib. Both patients had partial responses (PR) after crizotinib
treatment, and later developed acquired resistance [8]. The G1269A res-
idue is positioned at the end of the narrow ATP-binding pocket of ALK
where alanine signiﬁcantly compromises crizotinib binding due to ste-
ric hindrance. The G1269A ﬁnding in Patient 2's bone metastasis and
pleural effusions was the third case of a relapsed patient reported to
date with this particular mutation. Given these ﬁnding, it is conceivable
that ATP-binding pocket associated transformations are a more fre-
quent mechanism of crizotinib resistance in relapsed patients. WideTable 3
Barcoded fusion primer sequences.
Primer name Sequence
A-Barcode-Exon27F CCA TCT CAT CCC TGC GT
A-Barcode-Exon27R CCA TCT CAT CCC TGC GT
A-Barcode-Exon26F CCA TCT CAT CCC TGC GT
A-Barcode-Exon26R CCA TCT CAT CCC TGC GT
A-Barcode-Exon25F CCA TCT CAT CCC TGC GT
A-Barcode-Exon25R CCA TCT CAT CCC TGC GT
A-Barcode-Exon24F CCA TCT CAT CCC TGC GT
A-Barcode-Exon24R CCA TCT CAT CCC TGC GT
A-Barcode-Exon23F CCA TCT CAT CCC TGC GT
A-Barcode-Exon23R CCA TCT CAT CCC TGC GT
A-Barcode-Exon22F CCA TCT CAT CCC TGC GT
A-Barcode-Exon22R CCA TCT CAT CCC TGC GT
A-Barcode-Exon21F CCA TCT CAT CCC TGC GT
A-Barcode-Exon21R CCA TCT CAT CCC TGC GT
trP1-Exon27F CCT CTC TAT GGG CAG TC
trP1-Exon27R CCT CTC TAT GGG CAG TC
trP1-Exon26F CCT CTC TAT GGG CAG TC
trP1-Exon26R CCT CTC TAT GGG CAG TC
trP1-Exon25F CCT CTC TAT GGG CAG TC
trP1-Exon25R CCT CTC TAT GGG CAG TC
trP1-Exon24F CCT CTC TAT GGG CAG TC
trP1-Exon24R CCT CTC TAT GGG CAG TC
trP1-Exon23F CCT CTC TAT GGG CAG TC
trP1-Exon23R CCT CTC TAT GGG CAG TC
trP1-Exon22F CCT CTC TAT GGG CAG TC
trP1-Exon22R CCT CTC TAT GGG CAG TC
trP1-Exon21F CCT CTC TAT GGG CAG TC
trP1-Exon21R CCT CTC TAT GGG CAG TCspectrum of resistant mutations in the ALK kinase domain is one of
the major resistance mechanisms. Other possible resistance mecha-
nisms include the activation of compensatory signaling pathways that
are unaffected by ALK inhibitors. Therefore, once a patient develops ac-
quired resistance to a particular therapy, it is essential to quickly assess
the patient's tumor cell proﬁle to tailor speciﬁc treatment options.
Therein lies the need for an accurate and sensitive test since one third
of relapsed patients will have secondary mutations in their ALK gene.
In a recent study, new ALK inhibitors under active clinical development
have differential potencies against the different resistance mutations
[9]. With the knowledge of a patient's ALK-resistant mechanism, we
can strategically treat the patients with the second generation ALK
inhibitors or combinations with hsp90 inhibitors, chemotherapies,
or other TKIs to overcome acquired resistance and improve clinical
outcome.
We have developed a sensitive assay that can detect ALK secondary
mutations in FFPE samples from various tissue origins. A variety of
clinical samples collected from relapsed patients will be the source
for future mutation analysis. However, several challenges remain.G TCT CCG ACT CAG — BARCODE — GG TGT GTC TAT ATC CAT CTC CA
G TCT CCG ACT CAG — BARCODE — AG CAT ATG TGG CTC TGG ATA
G TCT CCG ACT CAG — BARCODE — GC AGG GCA GAT GCT TAA T
G TCT CCG ACT CAG — BARCODE — GG AGG ATG ATG GCT GAC TT
G TCT CCG ACT CAG — BARCODE — GC ATT TCC TTT CTT CCC AG
G TCT CCG ACT CAG — BARCODE — CA CAC CCC ATT CTT GAG G
G TCT CCG ACT CAG — BARCODE — CA CTG ACA AGC TCC TCG TC
G TCT CCG ACT CAG — BARCODE — AG CGA CAG GAT GAC AGG A
G TCT CCG ACT CAG — BARCODE — GA CTC AGC TCA GTT AAT TTT GG
G TCT CCG ACT CAG — BARCODE — CA GCA AAG ACT GGT TCT CAC
G TCT CCG ACT CAG — BARCODE — AG TTC TCA GCT CAC AGC CT
G TCT CCG ACT CAG — BARCODE — AC CCT CTC CAG GTT CTT TGG
G TCT CCG ACT CAG — BARCODE — CC TCA TTA TTG TGG CCT GT
G TCT CCG ACT CAG — BARCODE — AA GGG CAG GCT CAA GAG T
G GTG ATG GTG TGT CTA TAT CCA TCT CCA
G GTG ATA GCA TAT GTG GCT CTG GAT A
G GTG ATG CAG GGC AGA TGC TTA AT
G GTG ATC CCA GGA GCA CCA CCT TAT G
G GTG ATG CAT TTC CTT TCT TCC CAG
G GTG ATC ACA CCC CAT TCT TGA GG
G GTG ATC ACT GAC AAG CTC CTC GTC
G GTG ATA GCG ACA GGA TGA CAG GA
G GTG ATG ACT CAG CTC AGT TAA TTT TGG
G GTG ATC AGC AAA GAC TGG TTC TCA C
G GTG ATA GTT CTC AGC TCA CAG CCT
G GTG ATA CCC TCT CCA GGT TCT TTG G
G GTG ATC CTC ATT ATT GTG GCC TGT
G GTG ATA AGG GCA GGC TCA AGA GT
G1296A (G->C) C1156Y (G->A)
A B C
L1196M (T->G)
Fig. 2. Snapshot views of IVG viewer of mutations L1196M, C1156Y and G1296A. Panel A: mutation G1296A from Patient 2's tumor sample. Panel B: mutation C1156Y from Patient
7's dissected tumor sample. Panel C: mutation L1196M from Patient 8's tumor sample.
160 D. Huang et al. / Genomics 102 (2013) 157–162Rebiopsying tumors in relapsed patients may be difﬁcult because
they are usually in critical condition. Secondly, tumor content or
the ratio of mutant and normal cells could affect the detection limit
by diluting the mutant allele. Thirdly, the DNA in FFPE samples
could be poorly preserved, degraded and chemically-crosslinked.
We have shown that it is possible to extract genomic DNA from
FFPE samples and amplify it for downstream sequencing. DNA from
large resected tumorswas isolatedwith a column based DNA extraction
method. Small tissue sections or needle biopsies were extracted with a
commercial proteinase K lysis buffer kit. In this study, we successfully
ampliﬁed all amplicons using extracted genomic DNA from various
sample types including pleural ﬂuid and bronchoscopic biopsy in
FFPE. We were able to detect three mutations, C1156Y, L1196M and
G1269A, with an allele frequency between 12% and 15% in three patient
tumor samples. The assay was sensitive to detect mutant allele at 1.25%
level when we used a known mutation G1269A for a series of titration
experiments.
We successfully developed a simple strategy to assess the mutation
status of crizotinib-resistant tumor. Eight sets of PCR primers containing
barcodes and adapter sequences were placed into a 96 well plate for
PCR. All amplicons were pooled and directly added into Ion Torrent
sequencing workﬂow. The entire process using 8 to 16 samples per
sequencing run can be completed in three working days. We demon-
strated a sensitive and accurate deep sequencing approach that can
identify secondary ALKmutation from various forms of clinical samples.
This assay could be used in the clinical setting to help physicians quickly
choose treatment options to overcome crizotinib resistance and im-
prove patient outcome. Our base-pair speciﬁc error-weightedmutation
calling algorithm (BASCA) could also be applied to the other targeted
deep sequencing assays.Table 4
Barcode sequences.
Barcode Sequence
1 ACGAGTGCGT
2 ACGCTCGACA
3 AGACGCACTC
4 TCGATAGTGA
5 ATCAGACACG
6 ATATCGCGAG
7 CGTGTCTCTA
8 CTCGCGTGTC4. Materials and methods
4.1. Patients
Thirteen ALK fusion positive NSCLC patients were investigated after
acquired resistancewas developed during the course of crizotinib treat-
ment. Tumor sampleswere collected prior to the treatment and/or after
relapse and tested using approved protocols concordant with Institu-
tional Review Board in the three hospitals.4.2. Histologic examination of FFPE tumor samples
A 5 μm section was cut from the provided FFPE block and placed
onto a positive charged slide to air dry for 30 min and then heat
ﬁxed at 60 °C for 60 min. The slide was cooled, deparafﬁnized, and
stained with hematoxylin and eosin using the Leica Select Tech H&E
Staining System (Leica Microsystems Inc., Buffalo Grove, IL) and the
Leica Autostainer XL (Leica Microsystems Inc., Buffalo Grove, IL).
Tumor content was estimated during histological examination.4.3. Cell line and normal genomic DNA for titration experiments
NCI-H3122 cells (ATCC, Manassas, VA) were cultured in Gibco
RPMI 1640 (Cat# 22400-071, Life Technologies, Grand Island, NY),
10% FBS (Cat# 10437-028, Life Technologies, Grand Island, NY), and,
1% Penicillin Streptomycin (Cat# 15140-148, Life Technologies,
Grand Island, NY) under selection of increasing concentrations of
crizotinib increase of 2 fold every 2–3 weeks, starting at 100 nM and
ending at 1 μM after 10 weeks. These cells were then clonally selected
with cloning disks and indeﬁnitely maintained at 1 μM of crizotinib.
Of the resistance clones we isolated, clone 1-07 was identiﬁed to
possess the G1269A mutation within the EML4-ALK kinase domain.
Genomic DNA was extracted using a Qiagen DNeasy Blood & Tissue
Kit (Cat# 69504, Qiagen Inc., Valencia, CA). Normal human male
gDNA was obtained from Life Technologies (Cat# 360486, Life Tech-
nologies, Grand Island, NY).
161D. Huang et al. / Genomics 102 (2013) 157–1624.4. Titration experiment to determine assay sensitivity
Clone 1-07 genomic DNAwas diluted and titrated down to varying
percentages at 100%, 50%, 25%, 12.5%, 6.25% and 0% relative to the
normal human male gDNA. All samples were PCR-ampliﬁed and
barcoded with barcodes 1–6 and sequenced on an Ion Torrent PGM.
4.5. Genomic DNA extraction for ALK exon PCR
Genomic DNA was isolated from FFPE tumor sections with a
QiagenQIAamp®DNA FFPE Tissue Kit (Cat# 56404, Qiagen Inc., Valencia,
CA) according to the manufacturer's protocol. Alternatively, DNAs from
needle biopsies and small dissected tumor sections were extracted with
the Arcturus® PicoPure® DNA Extraction Kit (Cat# KIT0103, Life
Technologies, Grand Island, NY) using the manufacturer's “DNA Extrac-
tion Protocol: CapSure HS LCM Cap Samples”. Exons 21 to 27 corre-
sponding to the ALK tyrosine kinase domain were PCR-ampliﬁed and
barcoded from 20 ngQIAamp isolated genomic DNA or 10 μl PicoPure®
DNA Extraction lysateswith the Roche FastStart High Fidelity PCR system
(Cat# 03553361001, Roche Applied Science, Indianapolis, IN). PCR condi-
tions were set to the manufacturer's protocol. PCR primers and barcode
sequences are listed in Table 3 and 4. A primer master plate was created
to facilitate multichannel pipetting for PCR setup. A no template control
was included in the PCR setup using barcode 1 primer sets.
4.6. Sequencing on Ion Torrent Personal Genome MachineTM (PGM)
The DNA concentration for each amplicon was quantiﬁed on an
Agilent Bioanalyzer using the DNA 1000 chip (Cat# 5067-1504,
Agilent Technologies, Inc., Santa Clara, CA) according to the
manufacturer's protocol. The barcoded PCR amplicon templates were
equimolarly pooled and sequenced bi-directionally on an Ion Torrent
PGM (Life Technologies, Grand Island, NY) according to manufacturer's
protocols. A total of 2×108 DNA molecules library was constructed in
each sequencing run. The barcode-speciﬁc sample data was analyzed
by Life Technologies Torrent Suite version 2.2. Exported BAM ﬁles
were reviewed using Broad Institute's Integrative Genomics Viewer
(IGV) version 2.1. In IGV, the “Coverage allele-freq threshold” was set
to 0.01, the “Shade mismatched bases by quality” was set to 0 to 20.
4.7. BASCA algorithm and data analysis
Aligned sequence data were processed using Samtools [19]. The
results were piled up to obtain coverage data for both forward and re-
verse strands aswell as reads for individual nucleotides at each base loca-
tion. Mutation rate was deﬁned as the sum of reads from non-reference
nucleotides divided by the total coverage at each base location, expressed
in percent. A mutation is detected at base location i if its lower 95% con-
ﬁdence interval bound is above a threshold that is deﬁned as
Mti ¼ max Mci;Mbð Þ
whereMci is a base-speciﬁc threshold, based on the distribution of muta-
tion rate at base location i across samples, Mci ¼ x^i þ 4sið Þ2, where x^i is
the median of the square root transformed mutation rate across all
samples, and si is the robust standard deviation of the square root
transformed mutation rate, which is estimated using median absolute
deviation from median (MAD). Square root transformation helped to
normalize the data of small proportions. The use of 4 standard devia-
tions above median in the threshold determination helped to prevent
potential false positives as mutation is a rate event.Mb is a global back-
ground threshold for the mutation rate across all bases and samples. It
provides a protection of a small base-speciﬁc threshold due to poor es-
timate of variability from relatively small sample size. It was deﬁned as
the upper 95% conﬁdence bound (97.5 percentile) of the mutation rate
in this data. The threshold Mci provides a measure of noise level of themutation rate at base i, and we assumed that most of the data was not
mutated. For quality purpose, data with coverage below 200x were ex-
cluded. Mutation data were not of our interest if there was an extreme
strand bias (one strand has coverage of more than 10 times higher than
the other), inconsistent mutation between two strands, or at a base
where a common SNP was reported. All data were analyzed in R
v2.13.1 9 (r-project.org).
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